Search Browse Earnings

Lomond Therapeutics Holdings, Inc. — SlamSEC

Lomond Therapeutics Holdings, Inc.

Pharmaceutical Preparations·DOVER, DE

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

—

Adj. EBITDA

—

Net Income

-$9.9M

FY 2024

EPS (Diluted)

-$13.10

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$28.4M

FY 2024

Total Debt

$45,000

FY 2023

Net Cash

$28.4M

FY 2023

Enterprise Value

—

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

CEO

Dukes Iain D.